The U.S. Food and Drug Administration released revised requirements for the updating of the prescribing information for all currently licensed TNF inhibitors (etanercept, infliximab, adalimumab, golimumab, and certolizumab). Based on a recent review of post-marketing safety data, the agency is mandating that prescribers be aware of an increased event rate for malignancies in children and adolescents receiving this class of medications. Cases of leukemia in adults receiving TNF inhibitors and new onset psoriasis in users were also the subject of additions to prescribing requirements. A link to the summary of the requirements, designated as “for Healthcare Professionals” (including a summary of the data from which the requirements were based) can be found by following this link.
Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.
Use of this Site
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.